急性淋巴细胞白血病(ALL)对 FDA 批准靶向治疗和免疫治疗反应的预测 Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL). PubMed 2024/08/05 发表Curr Treat Options OncolQ1 · IF 5.8(JCR 2025) 人群:儿童人群:成人靶点:CD19靶点:CD20靶点:CD22急性淋巴细胞白血病 48.8分 ★★★☆☆ 站内排序·非疗效